QHP Closes $1.1 Billion Azurity Continuation Vehicle

A Single-Asset GP-Led Deal With Institutional Depth QHP Capital closed a $1.1 billion continuation vehicle for Azurity Pharmaceuticals, giving existing limited partners a choice between liquidity and rollover participation. HarbourVest led the transaction, with Pantheon Ventures and Audax Strategic Capital also involved, underscoring the continuing depth of institutional demand for seasoned, high-quality GP-led opportunities. The structure allows QHP to retain control of a pharmaceutical asset it continues to back with high conviction, while also bringing in fresh capital for organic growth, licensing activity, and potential M&A. That combination of sponsor conviction, asset familiarity, and tailored liquidity remains the core appeal of the GP-led market. Key Takeaways Single-asset continuation vehicles remain attractive when the asset quality is clear LPs are increasingly comfortable choosing between cash-out and rollover paths New capital is being paired with liquidity rather than used only for ownership transfer QHP said the vehicle provides liquidity to existing investors while securing long-term capital to support Azurity’s next phase of growth. Why This Matters for Private Markets For secondaries investors, the message is that the GP-led market is still rewarding specialization and underwriting depth. High-conviction assets with visible value-creation plans continue to attract large lead investors, and single-asset deals remain one of the cleanest ways to bridge the gap between exit-starved sponsors and LPs seeking optionality. Pricing power is likely to stay strongest in transactions where the sponsor can clearly articulate the next leg of growth.